Mercados españoles cerrados

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
116,09-1,91 (-1,62%)
Al cierre: 04:00PM EDT
116,09 0,00 (0,00%)
Después del cierre: 07:54PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Sector(es)Healthcare
SectorDiagnostics & Research
Empleados a tiempo completo10.590

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Jacob Thaysen Ph.D.CEO & Director796,63kN/A1975
Ms. Carissa L. RollinsChief Information Officer693,52kN/A1970
Mr. Charles E. Dadswell Esq.Senior VP & General Counsel1,03MN/A1959
Stephanie CamposPresidentN/AN/AN/A
Mr. Ankur DhingraChief Financial OfficerN/AN/A1976
Mr. Kevin Carl PegelsChief of Global OperationsN/AN/A1968
Mr. Scott EricksenVP & Chief Accounting OfficerN/AN/A1973
Dr. Steven Barnard Ph.D.Chief Technology OfficerN/AN/AN/A
Ms. Sallilyn SchwartzVice President of Investor RelationsN/AN/AN/A
Mr. Jakob WedelChief Strategy & Corporate Development Officer and CEO Chief of StaffN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de Illumina, Inc., a día 1 de julio de 2024, es 2. Las puntuaciones base son Auditoría: 5; Tablero: 1; Derechos de los accionistas: 2; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.